Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

A non-exhaustive repository of COVID-19 related scientific publications undertaken by LSHTM researchers since the beginning of the outbreak.

Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intrahospital Mortality of COVID-19.
De Lima Beltrão, FE; De Almeida Beltrão, DC; Carvalhal, G; De Lima Beltrão, FE; De Souza Braga Filho, J; De Brito Oliveira, J; De Jesus, JD S; Machado, GJ R; Dos Santos Silva, H; Teixeira, HM P; Rodrigues, JL; De Figueiredo, CA V; Dos Santos Costa, R; Hecht, F; Bianco, AC; Da Conceição Rodrigues Gonçalves, M; Ramos, HE;
2022
The Journal of clinical endocrinology and metabolism, (2022).107 6 10.1210/clinem/dgac075.
Covid-19: An urgent call for global "vaccines-plus" action.
An open letter by a group of public health experts,; Clinicians,; Scientists,;
2022
BMJ (Clinical research ed.), (2022).376, 10.1136/bmj.o1.
Social accountability and health systems' change, beyond the shock of Covid-19: drawing on histories of technical and activist approaches to rethink a shared code of practice.
Nelson, E; Waiswa, P; Coelho, VS; Sarriot, E;
2022
International journal for equity in health, (2022).21 Suppl 1 10.1186/s12939-022-01645-0.
COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?.
Akande, OW; Igumbor, EU; Elimian, KO; Ohonsi, CE; Nwozor, L; Oden, O; Ekpenyong, EN; Ndodo, N; Ike, IF; Egede, M; Nwachukwu, W; Onoja, AM; Fofah, JG; Azi, RI; Ochu, CL; ADETIFA, IM;
2022
Journal of global health, (2022).12, 10.7189/jogh.12.03055.
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies.
Fu, Y; Zhao, J; Wei, X; Han, P; Yang, L; Ren, T; Zhan, S; Li, L;
2022
Frontiers in public health, (2022).10, 10.3389/fpubh.2022.917732.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Liu, X; Munro, AP S; Feng, S; Janani, L; Aley, PK; Babbage, G; Baxter, D; Bula, M; Cathie, K; Chatterjee, K; Dejnirattisai, W; Dodd, K; Enever, Y; Qureshi, E; Goodman, AL; Green, CA; Harndahl, L; Haughney, J; Hicks, A; Van der Klaauw, AA; Kwok, J; Libri, V; Llewelyn, MJ; McGregor, AC; Minassian, AM; ... COV-BOOST study group,
2022
The Journal of infection, (2022).84 6 10.1016/j.jinf.2022.04.018.
Assessment of Cardiac, Vascular, and Pulmonary Pathobiology In Vivo During Acute COVID-19.
Alam, SR; Vinayak, S; Shah, A; Doolub, G; Kimeu, R; Horn, KP; Bowen, SR; Jeilan, M; Lee, KK; Gachoka, S; Riunga, F; Adam, RD; Vesselle, H; Joshi, N; Obino, M; Makhdomi, K; Ombati, K; Nganga, E; Gitau, S; Chung, MH; SHAH, AS V;
2022
Journal of the American Heart Association, (2022).11 18 10.1161/JAHA.122.026399.
The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence.
Carle, C; Hughes, S; Freeman, V; Campbell, D; Egger, S; Caruana, M; Hui, H; Yap, S; Deandrea, S; Onyeka, TC; IJzerman, MJ; Ginsburg, O; Bray, F; Sullivan, R; AGGARWAL, A; Peacock, SJ; Chan, KK W; Hanna, TP; Soerjomataram, I; O'Connell, DL; Canfell, K; Steinberg, J;
2022
Journal of Cancer Policy, (2022).33, 10.1016/j.jcpo.2022.100338.
Mitigating the effects of COVID-19 on HIV treatment and care in Lusaka, Zambia: a before-after cohort study using mixed effects regression.
Pry, JM; SIKOMBE, K; Mody, A; Iyer, S; Mutale, J; Vlahakis, N; Savory, T; Wa Mwanza, M; Mweebo, K; Mwila, A; Mwale, C; Mukumbwa-Mwenechanya, M; Kerkhoff, AD; Sikazwe, I; Bolton Moore, C; Mwamba, D; Geng, EH; Herce, ME;
2022
BMJ global health, (2022).7 1 10.1136/bmjgh-2021-007312.
Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis.
LIU, Y; PEARSON, CA B; Sandmann, FG; BARNARD, RC; Kim, J-H; CMMID COVID-19 Working Group,; FLASCHE, S; JIT, M; ABBAS, K;
2022
The Lancet Regional Health - Europe, (2022).17, 10.1016/j.lanepe.2022.100381.